James H. Kelly, President and CEO of Stem Cell Innovations, Inc., Talks to The Wall Street Transcript

The Wall Street Transcript has published an in-depth interview with James H. Kelly, President and CEO of Stem Cell innovations, Inc. (NASDAQ: SCLL), in which he talks at length about the Company.

The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm.

Stem Cell Innovations’ proprietary, human pluripotent stem cells, known as PluriCells™, have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research. Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell™ technology greatly expands the company’s currently marketed C3A human liver cell-based toxicology offerings

When asked about the company’s current position, Mr. Kelly stated, “We have a very practical outlook and are concentrated on the application of stem cells in drug and cell therapy. Our cells are outside the presidential ban, so that doesn’t affect our work, and I think the controversy will subside as people see real advances coming from stem cell research.”

Regarding the company’s objectives, Mr. Kelly stated, “Our objectives over the next year — get the cells to the universities, sign agreements with patient organizations, and, of course, get a couple of agreements with biotechnology or pharmaceutical companies.”

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.